A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
← catalyst calendarNCT06846671 · readout in 634 d
Sponsored by BeOne Medicines (industry) · ONC — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
250estimated
Sites
127
Countries
Argentina, Australia, Brazil +11
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-04-10 | actual | When the study began enrolling |
| Primary completion | 2028-05-15 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-02-14 | estimated | The whole study's end, after follow-up |
| First posted | 2025-02-26 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-07 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- CLL
- Chronic Lymphocytic Leukemia
Interventions
- Drug: BGB-16673
- Drug: Bendamustine
- Drug: Idelalisib
- Drug: Rituximab
- Drug: Venetoclax
Primary outcome
what the primary-completion date above is the date OFProgression-Free Survival (PFS) by Independent Review Committee (IRC)
measured Approximately 36 Months
Permalink · ONC's whole pipeline · Catalyst calendar · Every registered study · What changed